Inhibiting antibodies of ADAM10/17, CAECAM, or TIM-3, neutralizing sTIM-3, may reinvigorate the T cell response, particularly in anti-PD-1-resistant tumor patients.40 Here, ADAM10 is linked to neoplasm.